Tech Company Financing Transactions
Areteia Therapeutics Funding Round
On 7/12/2022, Areteia Therapeutics raised $350 million in Series A funding from Bain Capital Life Sciences and private investors.
Transaction Overview
Company Name
Announced On
7/12/2022
Transaction Type
Venture Equity
Amount
$350,000,000
Round
Series A
Investors
Bain Capital Life Sciences (Lead Investor) (Adam Koppel)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
50 Mountaintop Rd.
Bernardsville, NJ 07924
USA
Bernardsville, NJ 07924
USA
Phone
Undisclosed
Website
Email Address
Overview
Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners, whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jorge Bartolome
Chief Financial Officer
Chris Visioli
Chief Scientific Officer
Calman Prussin
VP - Bus. Development
Mark Kreston
VP - Bus. Development
Peter Wijngaard
VP - General Counsel
Chris Cox
VP - Human Resources
Richard Fires
VP - Regulatory Affairs
Lex Kay
Browse more venture capital transactions:
Prev: 7/12/2022: SERG Technologies venture capital transaction
Next: 7/12/2022: Wheelocity venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs